keyword
MENU ▼
Read by QxMD icon Read
search

renal carcinoma

keyword
https://www.readbyqxmd.com/read/28103578/prognostic-and-predictive-value-of-vhl-gene-alteration-in-renal-cell-carcinoma-a-meta-analysis-and-review
#1
Bum Jun Kim, Jung Han Kim, Hyeong Su Kim, Dae Young Zang
The von Hippel-Lindau (VHL) gene is often inactivated in sporadic renal cell carcinoma (RCC) by mutation or promoter hypermethylation. The prognostic or predictive value of VHL gene alteration is not well established. We conducted this meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. We searched PUBMED, MEDLINE and EMBASE for articles including following terms in their titles, abstracts, or keywords: 'kidney or renal', 'carcinoma or cancer or neoplasm or malignancy', 'von Hippel-Lindau or VHL', 'alteration or mutation or methylation', and 'prognostic or predictive'...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28103449/anatomical-templates-of-lymph-node-dissection-for-upper-tract-urothelial-carcinoma-a-systematic-review-of-the-literature
#2
R Campi, A Minervini, A Mari, G Hatzichristodoulou, F Sessa, A Lapini, M Sessa, J E Gschwend, S Serni, M Roscigno, M Carini
Indications and techniques of lymph node dissection (LND) for upper tract urothelial carcinoma (UTUC) are still controversial. Areas Covered: In this study, a systematic review of the English-language literature was performed up to July 1, 2016 using the Medline, Scopus, Cochrane Library and Web of Sciences databases to provide a detailed overview of the most commonly dissected surgical templates of LND for UTUC according to laterality and location of the tumor. Overall, sixteen studies were analyzed. Based on the shared experiences in the scientific literature, the LND template typically included: for right-sided tumors of the renal pelvis, upper third and middle third of the ureter, the renal hilar, paracaval, precaval and retrocaval nodes, while for left-sided tumors the renal hilar, paraaortic and preaortic nodes...
January 19, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28103447/pharmacotherapy-for-treating-metastatic-clear-cell-renal-cell-carcinoma
#3
Camillo Porta, Silvia Chiellino, Alessandra Ferrari, Sara Mariucci, Wanda Liguigli
Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far...
January 19, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28101903/development-and-characterization-of-anti-glycopeptide-monoclonal-antibodies-against-human-podoplanin-using-glycan-deficient-cell-lines-generated-by-crispr-cas9-and-talen
#4
Mika K Kaneko, Takuro Nakamura, Ryusuke Honma, Satoshi Ogasawara, Yuki Fujii, Shinji Abe, Michiaki Takagi, Hiroyuki Harada, Hiroyoshi Suzuki, Yasuhiko Nishioka, Yukinari Kato
Human podoplanin (hPDPN), which binds to C-type lectin-like receptor-2 (CLEC-2), is involved in platelet aggregation and cancer metastasis. The expression of hPDPN in cancer cells or cancer-associated fibroblasts indicates poor prognosis. Human lymphatic endothelial cells, lung-type I alveolar cells, and renal glomerular epithelial cells express hPDPN. Although numerous monoclonal antibodies (mAbs) against hPDPN are available, they recognize peptide epitopes of hPDPN. Here, we generated a novel anti-hPDPN mAb, LpMab-21...
January 19, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28101217/safety-and-effectiveness-of-percutaneous-radiofrequency-ablation-in-early-stage-renal-cell-carcinoma
#5
Hang Liu, Changzhong Gao, Hualong Yu
The purpose of this study was to analyze the safety and effectiveness of percutaneous radiofrequency ablation (RFA) in early stage renal cell carcinoma. A total of 76 patients suffering from early stage renal cell carcinoma were selected and randomly assigned into the observation group (41 cases) or the control group (35 cases). Percutaneous RFA was used in the observation group, while retroperitoneoscopic radical operation of renal cell carcinoma was used in the control group, and the operative effects were compared...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28100397/replication-study-discovery-and-preclinical-validation-of-drug-indications-using-compendia-of-public-gene-expression-data
#6
Irawati Kandela, Fraser Aird
In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data" (Sirota et al., 2011). Here we report the results of those experiments. We found that cimetidine treatment in a xenograft model using A549 lung adenocarcinoma cells resulted in decreased tumor volume compared to vehicle control; however, while the effect was in the same direction as the original study (Figure 4C; Sirota et al...
January 19, 2017: ELife
https://www.readbyqxmd.com/read/28099931/a-new-semisynthetic-cardenolide-analog-3%C3%AE-2-1-amantadine-1-on-ethylamine-digitoxigenin-amantadig-affects-g2-m-cell-cycle-arrest-and-mirna-expression-profiles-and-enhances-proapoptotic-survivin-2b-expression-in-renal-cell-carcinoma-cell-lines
#7
Elke Nolte, Sven Wach, Izabella Thais Silva, Sabine Lukat, Arif B Ekici, Jennifer Munkert, Frieder Müller-Uri, Wolfgang Kreis, Cláudia Maria Oliveira Simões, Julio Vera, Bernd Wullich, Helge Taubert, Xin Lai
Cardiac glycosides are well known in the treatment of cardiovascular diseases; however, their application as treatment option for cancer patients is under discussion. We showed that the cardiac glycoside digitoxin and its analog AMANTADIG can inhibit the growth of renal cell carcinoma (RCC) cell lines and increase G2/M cell cycle arrest. To identify the signaling pathways and molecular basis of this G2/M arrest, microRNAs were profiled using microRNA arrays. Cardiac glycoside treatment significantly deregulated two microRNAs, miR-2278 and miR-670-5p...
January 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28099901/efficacy-of-sequential-therapies-with-sorafenib-sunitinib-versus-sunitinib-sorafenib-in-metastatic-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#8
REVIEW
Tingyu Wen, Hai Xiao, Chao Luo, Li Huang, Meimei Xiong
The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial and not answered clearly until now. This meta-analysis aims to estimate the efficacy of receptor tyrosine kinase inhibitors sorafenib-sunitinib and sunitinib-sorafenib for metastatic renal cell carcinoma, on the outcome of first-line progression-free survival, second-line progression-free survival, total progression-free survival and overall survival...
January 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28098906/mir%C3%A2-15a%C3%A2-5p-acts-as-an-oncogene-in-renal-cell-carcinoma
#9
Lu Jin, Yifan Li, Tao He, Jia Hu, Jiaju Liu, Mingwei Chen, Zeng Zhang, Yaoting Gui, Xiangming Mao, Shangqi Yang, Yongqing Lai
miRNAs have been reported to be involved in multiple cellular processes and the tumorigenesis of various cancers. miR‑15a‑5p (also termed miR‑15a) has previously been determined to be upregulated in renal cell carcinoma (RCC) by microarray profile. However, the expression and function of miR‑15a‑5p in RCC remain to be validated. In the present study, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to detect the expression levels of miR‑15a‑5p in RCC tissues and cells...
January 16, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28098572/metastatic-organotropism-an-intrinsic-property-of-breast-cancer-molecular-subtypes
#10
Shi Wei, Gene P Siegal
It has long been known that some cancers have the propensity to metastasize to certain organs thus creating a nonrandom distribution of sites for distant relapse, a phenomenon known as "metastatic organotropism." Some of these examples include ovary primary to abdominal cavity, prostate primary to bone, and pancreas primary to liver. In contrast, other tumor types, such as mammary and renal cell carcinoma, can relapse in multiple organs although approximately half of advanced breast cancers metastasize to bone...
January 16, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28097229/anti-sirp%C3%AE-antibodies-as-a-potential-new-tool-for-cancer-immunotherapy
#11
Tadahiko Yanagita, Yoji Murata, Daisuke Tanaka, Sei-Ichiro Motegi, Eri Arai, Edwin Widyanto Daniwijaya, Daisuke Hazama, Ken Washio, Yasuyuki Saito, Takenori Kotani, Hiroshi Ohnishi, Per-Arne Oldenborg, Noel Verjan Garcia, Masayuki Miyasaka, Osamu Ishikawa, Yae Kanai, Takahide Komori, Takashi Matozaki
Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRPα is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRPα Ab that blocks the interaction with CD47 markedly suppressed tumor formation by renal cell carcinoma or melanoma cells in immunocompetent syngeneic mice...
January 12, 2017: JCI Insight
https://www.readbyqxmd.com/read/28096985/radioactive-seed-localization-of-renal-cell-carcinoma-in-a-patient-with-von-hippel-lindau-disease
#12
Christina Marie Schiøttz Hassing, Tove Filtenborg Tvedskov, Niels Kroman, Thomas Levin Klausen, Sissal Djurhuus, Linnea Langhans
This report describes the case of a patient, who had successful radioactive seed localization (RSL) performed to improve the identification and excision of a renal cell carcinoma. RSL is a new method of preoperative localization, which can ease the surgical procedure, minimize tissue trauma, and ultimately benefit the patient.
January 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28096940/the-next-10-years-challenges-for-the-future-and-overcoming-resistance-to-targeted-therapies-for-renal-cell-carcinoma
#13
REVIEW
Daniel Y C Heng
The introduction of targeted therapies over the past 10 years revolutionized the treatment of metastatic renal cell carcinoma (mRCC). The next 10 years hold promise for even greater expansion of the therapeutic armamentarium for mRCC. A number of recently completed and ongoing trials have explored the use of antivascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the adjuvant setting, the use of predictive biomarkers to guide personalized medicine, as well as new systemic treatments and combination therapies for mRCC...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096937/sunitinib-side-effects-as-surrogate-biomarkers-of-efficacy
#14
REVIEW
Christian Kollmannsberger
With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse events, including hypertension, hypothyroidism, hand-foot syndrome, and neutropenia, have been explored as potential biomarkers of the clinical efficacy of sunitinib in mRCC and are reviewed in this article.
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096936/treatment-options-in-advanced-renal-cell-carcinoma-after-first-line-treatment-with-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors
#15
REVIEW
Naveen S Basappa
Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago and since then, a number of therapeutic options have been developed. Vascular endothelial growth factor-targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the second-line setting has typically been with either axitinib or everolimus. However, with the advent of several new agents demonstrating efficacy in the second-line setting, including nivolumab, cabozantinib, and the combination of lenvatinib and everolimus, the treatment paradigm has shifted toward these novel therapies with improved patient outcomes...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096935/practical-first-line-management-of-renal-cell-carcinoma-in-a-community-practice
#16
REVIEW
Henry Conter
Sunitinib is an oral receptor tyrosine kinase inhibitor (TKI) that targets signalling by vascular endothelial growth factor receptors (VEGFRs). The standard sunitinib dosing schedule for metastatic renal cell carcinoma (mRCC) is 50 mg for four weeks (28 days) of treatment, followed by a two-week (14-day) break from treatment (four/two schedule). However, this schedule is associated with toxicities that can limit the patient's health-related quality of life (HRQOL) and impede treatment compliance. Given the generally incurable nature of mRCC and the toxicity associated with therapy, treatment strategies should focus on achieving long-term response, preserving HRQOL, and minimizing treatment-related toxicity...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096934/first-line-treatment-options-in-metastatic-renal-cell-cancer
#17
REVIEW
Anil Kapoor
The introduction of targeted therapy a decade ago revolutionized the treatment of metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR). Currently recommended first-line treatments in Canada include sunitinib, pazopanib, and temsirolimus. With the heterogeneity of mRCC disease, the choice of treatment is driven largely by prognostic factors...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096929/tremendous-non-progressed-chromophobe-renal-cell-carcinoma-for-eight-years-performed-by-laparoscope
#18
Yanbo Wang, Xiaobo Ding, Xiaobo Ma, Lingbo Yang, Faping Li, Chunxi Wang, Yuchuan Hou
The prognostic role of chromophobe renal cell carcinoma (ChRCC) is still controversial. Here, we report on a patient who lived with tremendous non-progressed renal malignant tumour for eight years. The 32-year-old patient presented to our hospital with a huge renal tumour. Computed tomography (CT) scan showed a tumour 12 cm in diameter at the upper pole of the right kidney. Trans-abdominal laparoscopic right radical nephrectomy was performed. Histopathological examination confirmed this tumour to be a ChRCC...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28096912/mortality-trends-and-the-impact-of-lymphadenectomy-on-survival-for-renal-cell-carcinoma-patients-with-distant-metastasis
#19
Hiten D Patel, Michael A Gorin, Natasha Gupta, Max Kates, Michael H Johnson, Phillip M Pierorazio, Mohamad E Allaf
INTRODUCTION: Current treatment paradigms for metastatic renal cell carcinoma (mRCC) invoke a combination of surgical and systemic therapies. We sought to quantify trends in mortality and performance of lymphadenectomy, as well as impact on survival for patients with mRCC. METHODS: The Surveillance, Epidemiology, and End Results registry (SEER) (1988-2011) identified patients with mRCC. Kaplan-Meier curves and Cox proportional hazards models with competing risks regression were employed to assess survival...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28095383/evaluation-of-plasmatic-kisspetin-10-as-a-biomarker-for-malignancy-and-subtype-differentiation-in-small-renal-tumours
#20
Marcus Horstmann, Felix Krause, Daniel Steinbach, Lars Twelker, Marc-Oliver Grimm
OBJECTIVE: To evaluate Kisspeptin-10 (Kiss-10) in patients with small renal tumours (SRTs) and controls. MATERIAL AND METHODS: Kiss-10 was measured in preoperative plasma samples in a cohort of 143 patients with unilateral renal tumours smaller than or equal to 4 cm and 40 age-matched controls by a competitive ELISA test kit. The cohort of patients included 56 patients with clear cell renal cell carcinoma (ccRCC), 43 with papillary RCC (pRCC), 12 with chromophobe RCC (chRCC) and 32 with oncocytomas...
January 18, 2017: Urologia Internationalis
keyword
keyword
21147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"